India's first approved dengue vaccine, Qdenga (TAK-003), developed by Takeda, received CDSCO marketing authorisation in July 2026 for ages 4-60. Dr. Reddy's will promote and distribute it in the private market from the first half of 2027, while Takeda retains public market rights. This marks a critical step in addressing India's 11-fold rise in dengue cases over two decades.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Vaccine Name: Qdenga (TAK-003)
- ›Regulatory Approval: CDSCO marketing authorisation in July 2026
- ›Target this Data: Qdenga (TAK-003) – India's first approved dengue vaccine; CDSCO approval July 2026; Age group 4-60 years; Two-dose regimen three months apart; Availability first half of 2027.
- ›Target this Nodal Body: Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health and Family Welfare.
- ›Target this Legal Point: Marketing authorisation by CDSCO for a live-attenuated tetravalent dengue vaccine; Dr. Reddy's as exclusive private market distributor; Takeda retains public market rights.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.